| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.02 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.02 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.094 | 0.02 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.089 | 0.02 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.15 | 0.02 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.02 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.02 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.075 | 0.02 |